- Home
- FEBO vs ADXN Comparison
FEBO vs ADXN Comparison
Compare FEBO & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- ADXN
- Stock Information
- Founded
- FEBO 1993
- ADXN 2002
- Country
- FEBO Hong Kong
- ADXN Switzerland
- Employees
- FEBO N/A
- ADXN N/A
- Industry
- FEBO
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- ADXN Health Care
- Exchange
- FEBO Nasdaq
- ADXN Nasdaq
- Market Cap
- FEBO 8.3M
- ADXN 8.1M
- IPO Year
- FEBO 2023
- ADXN N/A
- Fundamental
- Price
- FEBO $0.71
- ADXN $8.81
- Analyst Decision
- FEBO
- ADXN
- Analyst Count
- FEBO 0
- ADXN 0
- Target Price
- FEBO N/A
- ADXN N/A
- AVG Volume (30 Days)
- FEBO 16.5K
- ADXN 22.2K
- Earning Date
- FEBO 11-25-2025
- ADXN 11-10-2025
- Dividend Yield
- FEBO N/A
- ADXN N/A
- EPS Growth
- FEBO N/A
- ADXN N/A
- EPS
- FEBO N/A
- ADXN N/A
- Revenue
- FEBO $17,110,653.00
- ADXN $210,347.00
- Revenue This Year
- FEBO N/A
- ADXN $86.57
- Revenue Next Year
- FEBO N/A
- ADXN N/A
- P/E Ratio
- FEBO N/A
- ADXN N/A
- Revenue Growth
- FEBO 11.58
- ADXN N/A
- 52 Week Low
- FEBO $0.61
- ADXN $6.51
- 52 Week High
- FEBO $3.34
- ADXN $12.05
- Technical
- Relative Strength Index (RSI)
- FEBO 45.29
- ADXN 47.70
- Support Level
- FEBO $0.69
- ADXN $8.50
- Resistance Level
- FEBO $0.85
- ADXN $9.00
- Average True Range (ATR)
- FEBO 0.06
- ADXN 0.50
- MACD
- FEBO -0.01
- ADXN -0.09
- Stochastic Oscillator
- FEBO 10.37
- ADXN 20.95
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.